Clinical Trial Update: Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography [Phase 2]

View source ↗

Summary

Phase 2 intra-individual dose comparison study of Magnevist for magnetic resonance angiography has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease
• Peripheral Vascular Disease

Drugs mentioned

• Magnevist (gadopentetate dimeglumine)

Snippet

Sponsor: Bayer | Conditions: Magnetic Resonance Angiography, Peripheral Vascular Diseases | Phase 2 | Status: COMPLETED